A Randomized, Double-Blind, Placebo-Controlled Phase II Study of ARQ 197 (Tivantinib) in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Tivantinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 07 Aug 2018 Results (n=80) published in the Investigational New Drugs.
- 10 Jun 2017 Biomarkers information updated
- 21 Apr 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2017.